You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClarithromycin
Accession NumberDB01211  (APRD00181)
TypeSmall Molecule
GroupsApproved
DescriptionClarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Structure
Thumb
Synonyms
6-O-methyl erythromycin
6-O-Methylerythromycin
6-O-Methylerythromycin a
CLA
CLARITHROMYCIN
Clarithromycina
Clarithromycine
Clarithromycinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-clarithromycinGranule, for suspension250 mgOralAccel Pharma Inc2012-09-04Not applicableCanada
Accel-clarithromycinGranule, for suspension125 mgOralAccel Pharma Inc2012-09-04Not applicableCanada
Act Clarithromycin XLTablet, extended release500 mgOralActavis Pharma Company2014-12-01Not applicableCanada
Ava-clarithromycinTablet250 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-clarithromycinTablet500 mgOralAvanstra Inc2011-09-192014-08-21Canada
BiaxinTablet, film coated, extended release500 mg/1OralPhysicians Total Care, Inc.2000-11-03Not applicableUs
BiaxinTablet, film coated, extended release500 mg/1OralAbb Vie Inc.2000-03-032016-10-13Us
BiaxinTablet, film coated250 mg/1OralAbb Vie Inc.1991-10-31Not applicableUs
BiaxinTablet, film coated500 mg/1OralA S Medication Solutions Llc1991-10-31Not applicableUs
BiaxinTablet, film coated500 mg/1OralCardinal Health1991-10-31Not applicableUs
BiaxinTablet, film coated500 mg/1OralAbb Vie Inc.1991-10-31Not applicableUs
BiaxinTablet, film coated, extended release500 mg/1OralA S Medication Solutions Llc2000-03-03Not applicableUs
BiaxinGranule, for suspension125 mg/5mLOralAbb Vie Inc.1993-12-23Not applicableUs
BiaxinTablet, film coated500 mg/1OralREMEDYREPACK INC.2013-02-25Not applicableUs
BiaxinGranule, for suspension250 mg/5mLOralPhysicians Total Care, Inc.2007-05-01Not applicableUs
BiaxinGranule, for suspension250 mgOralBgp Pharma Ulc2002-05-28Not applicableCanada
BiaxinGranule, for suspension250 mg/5mLOralAbb Vie Inc.1993-12-23Not applicableUs
BiaxinTablet, film coated250 mg/1OralREMEDYREPACK INC.2013-03-13Not applicableUs
BiaxinGranule, for suspension125 mgOralBgp Pharma Ulc1995-12-31Not applicableCanada
Biaxin BidTablet250 mgOralBgp Pharma Ulc1992-12-31Not applicableCanada
Biaxin BidTablet500 mgOralBgp Pharma Ulc1994-12-31Not applicableCanada
Biaxin XLTablet, extended release500 mgOralBgp Pharma Ulc2002-05-22Not applicableCanada
ClarithromycinTablet250 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
ClarithromycinFor suspension125 mg/5mLOralZydus Pharmaceuticals USA Inc1991-10-31Not applicableUs
ClarithromycinTablet500 mgOralPro Doc Limitee2009-10-08Not applicableCanada
ClarithromycinTablet500 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
ClarithromycinFor suspension250 mg/5mLOralZydus Pharmaceuticals USA Inc1991-10-31Not applicableUs
ClarithromycinTablet500 mg/1OralKAISER FOUNDATION HOSPITALS2009-10-01Not applicableUs
ClarithromycinGranule, for suspension125 mgOralSanis Health Inc2013-09-05Not applicableCanada
ClarithromycinTablet250 mgOralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
ClarithromycinTablet, film coated250 mg/1OralZydus Pharmaceuticals USA Inc1991-10-31Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralPreferred Pharmaceuticals Inc.2016-09-28Not applicableUs
ClarithromycinGranule, for suspension250 mgOralSanis Health Inc2013-09-05Not applicableCanada
ClarithromycinTablet500 mgOralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
ClarithromycinTablet, film coated500 mg/1OralZydus Pharmaceuticals USA Inc1991-10-31Not applicableUs
ClarithromycinTablet250 mgOralPro Doc Limitee2009-10-08Not applicableCanada
Dom-clarithromycinTablet500 mgOralDominion Pharmacal2010-10-01Not applicableCanada
Mylan-clarithromycinTablet500 mgOralMylan Pharmaceuticals Ulc2007-07-26Not applicableCanada
Mylan-clarithromycinTablet250 mgOralMylan Pharmaceuticals Ulc2007-07-26Not applicableCanada
PMS-clarithromycinTablet500 mgOralPharmascience Inc2007-08-10Not applicableCanada
PMS-clarithromycinTablet250 mgOralPharmascience Inc2007-08-10Not applicableCanada
Ran-clarithromycinTablet250 mgOralRanbaxy Pharmaceuticals Canada Inc.2011-02-01Not applicableCanada
Ran-clarithromycinTablet500 mgOralRanbaxy Pharmaceuticals Canada Inc.2011-02-01Not applicableCanada
Ran-clarithromycinGranule, for suspension250 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-clarithromycinGranule, for suspension125 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-clarithromycin XLTablet, extended release500 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ratio-clarithromycinTablet500 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-07-262014-09-19Canada
Ratio-clarithromycinTablet250 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-07-262014-09-19Canada
Riva-clarithromycinTablet250 mgOralLaboratoire Riva Inc2010-06-162013-07-31Canada
Riva-clarithromycinTablet500 mgOralLaboratoire Riva Inc2010-06-16Not applicableCanada
Sandoz ClarithromycinTablet250 mgOralSandoz Canada Incorporated2008-06-06Not applicableCanada
Sandoz ClarithromycinTablet500 mgOralSandoz Canada Incorporated2008-06-06Not applicableCanada
Sandoz Clarithromycin XLTablet, extended release500 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Teva-clarithromycinTablet250 mgOralTeva Canada Limited2012-05-09Not applicableCanada
Teva-clarithromycinTablet500 mgOralTeva Canada Limited2012-05-09Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clarithromycinTablet250 mgOralApotex Inc2007-07-26Not applicableCanada
Apo-clarithromycinTablet500 mgOralApotex Inc2007-07-26Not applicableCanada
Apo-clarithromycin XLTablet, extended release500 mgOralApotex Inc2014-09-03Not applicableCanada
ClarithromycinTablet500 mg/1OralPar Pharmaceutical, Inc.2016-06-20Not applicableUs
ClarithromycinTablet500 mg/1OralREMEDYREPACK INC.2010-03-25Not applicableUs
ClarithromycinTablet500 mg/1OralRebel Distributors Corp.2005-08-25Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralREMEDYREPACK INC.2013-05-092016-04-05Us
ClarithromycinTablet, film coated250 mg/1OralWockhardt USA LLC.2006-05-31Not applicableUs
ClarithromycinTablet, film coated, extended release500 mg/1OralDepartment Of State Health Services, Pharmacy Branch2008-01-01Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralBlenheim Pharmacal, Inc.2012-10-05Not applicableUs
ClarithromycinFor suspension125 mg/5mLOralSandoz Inc2007-09-04Not applicableUs
ClarithromycinTablet, film coated, extended release500 mg/1OralMayne Pharma Inc.2016-08-03Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralTeva Pharmaceuticals USA Inc2005-06-282016-08-31Us
ClarithromycinTablet, film coated250 mg/1OralSunshine Lake Pharma Co., Ltd.2015-09-29Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralRanbaxy Pharmaceuticals Inc.2005-05-25Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2006-05-31Not applicableUs
ClarithromycinTablet500 mg/1OralLife Line Home Care Services, Inc.2011-12-08Not applicableUs
ClarithromycinTablet, coated500 mg/1OralWest Ward Pharmaceuticals Corp.2004-05-25Not applicableUs
ClarithromycinFor suspension250 mg/5mLOralA S Medication Solutions2007-09-04Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralLannett Company, Inc.2015-12-04Not applicableUs
ClarithromycinTablet, film coated, extended release500 mg/1OralPd Rx Pharmaceuticals, Inc.2008-01-01Not applicableUs
ClarithromycinTablet250 mg/1OralREMEDYREPACK INC.2011-06-272016-10-21Us
ClarithromycinTablet, coated500 mg/1Oralbryant ranch prepack2004-05-25Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralApotex Corp2007-09-13Not applicableUs
ClarithromycinTablet500 mg/1OralPreferred Pharmaceuticals Inc.2016-06-15Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralKAISER FOUNDATION HOSPITALS2010-10-27Not applicableUs
ClarithromycinTablet, film coated, extended release500 mg/1OralDispensing Solutions, Inc.2008-01-01Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralCitron Pharma LLC2012-07-25Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralA S Medication Solutions2012-07-25Not applicableUs
ClarithromycinTablet, coated250 mg/1OralA S Medication Solutions2004-05-25Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralAidarex Pharmaceuticals LLC2006-05-31Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralREMEDYREPACK INC.2014-03-03Not applicableUs
ClarithromycinGranule, for suspension125 mg/5mLOralRanbaxy Pharmaceuticals Inc.2007-10-03Not applicableUs
ClarithromycinTablet250 mg/1OralAvera Mc Kennan Hospital2015-05-01Not applicableUs
ClarithromycinFor suspension250 mg/5mLOralSandoz Inc2007-09-04Not applicableUs
ClarithromycinTablet, coated250 mg/1OralA S Medication Solutions2004-11-22Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralTeva Pharmaceuticals USA Inc2005-06-282016-11-30Us
ClarithromycinTablet500 mg/1OralREMEDYREPACK INC.2011-04-202016-10-13Us
ClarithromycinTablet, film coated500 mg/1OralWockhardt Limited2006-05-31Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralAllied Pharma Inc2012-12-31Not applicableUs
ClarithromycinTablet, film coated, extended release500 mg/1OralTeva Pharmaceuticals USA Inc2006-06-23Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralA S Medication Solutions2012-07-25Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralLannett Company, Inc.2015-12-04Not applicableUs
ClarithromycinTablet500 mg/1OralPd Rx Pharmaceuticals, Inc.2005-08-25Not applicableUs
ClarithromycinTablet, coated500 mg/1OralBlenheim Pharmacal, Inc.2015-12-02Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralREMEDYREPACK INC.2011-05-122016-11-29Us
ClarithromycinTablet250 mg/1Oralbryant ranch prepack2005-10-18Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralProficient Rx LP2012-07-25Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralAurobindo Pharma Limited2012-07-25Not applicableUs
ClarithromycinTablet500 mg/1OralAmerican Health Packaging2014-04-16Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralCitron Pharma LLC2012-07-25Not applicableUs
ClarithromycinTablet, coated500 mg/1OralA S Medication Solutions2004-05-25Not applicableUs
ClarithromycinTablet500 mg/1OralRed Pharm Drug, Inc.2005-08-25Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralAidarex Pharmaceuticals LLC2006-05-31Not applicableUs
ClarithromycinFor suspension250 mg/5mLOralPhysicians Total Care, Inc.2008-03-04Not applicableUs
ClarithromycinGranule, for suspension250 mg/5mLOralRanbaxy Pharmaceuticals Inc.2007-10-03Not applicableUs
ClarithromycinTablet500 mg/1OralClinical Solutions Wholesale2005-08-25Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralA S Medication Solutions2012-07-25Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralTeva Pharmaceuticals USA Inc2014-12-16Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralREMEDYREPACK INC.2011-05-042016-10-13Us
ClarithromycinTablet, film coated, extended release500 mg/1OralPd Rx Pharmaceuticals, Inc.2008-01-01Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralWockhardt Limited2006-05-31Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralAllied Pharma Inc2012-12-31Not applicableUs
ClarithromycinTablet250 mg/1OralSandoz Inc2005-10-18Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralAv Pak2016-10-10Not applicableUs
ClarithromycinTablet250 mg/1OralRebel Distributors Corp.2005-10-18Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-11-15Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralWockhardt USA LLC.2006-05-31Not applicableUs
ClarithromycinTablet500 mg/1OralAvera Mc Kennan Hospital2015-03-02Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralAurobindo Pharma Limited2012-07-25Not applicableUs
ClarithromycinTablet500 mg/1OralPreferred Pharmaceuticals, Inc2005-10-05Not applicableUs
ClarithromycinTablet, coated250 mg/1OralWest Ward Pharmaceuticals Corp.2004-05-25Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralA S Medication Solutions2006-05-31Not applicableUs
ClarithromycinTablet, film coated, extended release500 mg/1OralActavis Pharma, Inc.2008-01-01Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralRebel Distributors Corp2006-05-31Not applicableUs
ClarithromycinTablet500 mg/1OralPhysicians Total Care, Inc.2005-10-05Not applicableUs
ClarithromycinTablet, extended release500 mg/1Oralbryant ranch prepack2009-05-30Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralApotex Corp2007-09-13Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralProficient Rx LP2015-12-04Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralTeva Pharmaceuticals USA Inc2014-12-16Not applicableUs
ClarithromycinTablet250 mg/1OralREMEDYREPACK INC.2011-06-012016-10-13Us
ClarithromycinTablet, film coated500 mg/1OralSunshine Lake Pharma Co., Ltd.2015-09-29Not applicableUs
ClarithromycinTablet, film coated250 mg/1OralRanbaxy Pharmaceuticals Inc.2005-05-25Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralAmerican Health Packaging2013-06-202015-11-30Us
ClarithromycinTablet500 mg/1OralSandoz Inc2005-08-25Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralAv Pak2016-10-10Not applicableUs
Clarithromycin 250 mgTablet, film coated250 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-10-12Not applicableUs
Clarithromycin 500 mgTablet, film coated500 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-10-12Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Klacid XLNot Available
Klaricid XLNot Available
MacladinNot Available
NaxyNot Available
VeclamNot Available
ZeclarNot Available
Brand mixtures
NameLabellerIngredients
Hp-pacTakeda Pharmaceuticals America Inc
Lansoprazole, Amoxicillin, and ClarithromycinTeva Pharmaceuticals USA Inc
Lansoprazole, Amoxicillin, ClarithromycinCitron Pharma LLC
Omeclamox-pakPernix Therapeutics, LLC
SaltsNot Available
Categories
UNIIH1250JIK0A
CAS number81103-11-9
WeightAverage: 747.9534
Monoisotopic: 747.476891299
Chemical FormulaC38H69NO13
InChI KeyAGOYDEPGAOXOCK-KCBOHYOISA-N
InChI
InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
SMILES
[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[[email protected]](C)O1)O[[email protected]]1[[email protected]](C)[C@@H](O[C@]2([H])O[[email protected]](C)C[C@@H]([[email protected]]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[[email protected]](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
Pharmacology
IndicationAn alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).
Structured Indications
PharmacodynamicsClarithromycin is a macrolide antibiotic whose spectrum of activity includes many gram-positive (Staphylococcus aureus, S. pneumoniae, and S. pyogenes) and gram-negative aerobic bacteria (Haemophilus influenzae, H. parainfluenzae, and Moraxella catarrhalis), many anaerobic bacteria, some mycobacteria, and some other organisms including Mycoplasma, Ureaplasma, Chlamydia, Toxoplasma, and Borrelia. Other aerobic bacteria that clarithromycin has activity against include C. pneumoniae and M. pneumoniae. Clarithromycin has an in-vitro activity that is similar or greater than that of erythromycin against erythromycin-susceptible organisms. Clarithromycin is usually bacteriostatic, but may be bactericidal depending on the organism and the drug concentration.
Mechanism of actionClarithromycin is first metabolized to 14-OH clarithromycin, which is active and works synergistically with its parent compound. Like other macrolides, it then penetrates bacteria cell wall and reversibly binds to domain V of the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome, blocking translocation of aminoacyl transfer-RNA and polypeptide synthesis. Clarithromycin also inhibits the hepatic microsomal CYP3A4 isoenzyme and P-glycoprotein, an energy-dependent drug efflux pump.
TargetKindPharmacological actionActionsOrganismUniProt ID
50S ribosomal protein L10Proteinyes
inhibitor
Shigella flexneriP0A7J6 details
Potassium voltage-gated channel subfamily H member 2ProteinunknownNot AvailableHumanQ12809 details
Solute carrier organic anion transporter family member 1B1ProteinunknownNot AvailableHumanQ9Y6L6 details
Solute carrier organic anion transporter family member 1B3ProteinunknownNot AvailableHumanQ9NPD5 details
Related Articles
AbsorptionClarithromycin is well-absorbed, acid stable and may be taken with food.
Volume of distributionNot Available
Protein binding~ 70% protein bound
Metabolism

Hepatic - predominantly metabolized by CYP3A4 resulting in numerous drug interactions.

SubstrateEnzymesProduct
Clarithromycin
14-hydroxyclarithromycinDetails
Clarithromycin
N-desmethylclarithromycinDetails
Route of eliminationAfter a 250 mg tablet every 12 hours, approximately 20% of the dose is excreted in the urine as clarithromycin, while after a 500 mg tablet every 12 hours, the urinary excretion of clarithromycin is somewhat greater, approximately 30%.
Half life3-4 hours
ClearanceNot Available
ToxicitySymptoms of toxicity include diarrhea, nausea, abnormal taste, dyspepsia, and abdominal discomfort. Transient hearing loss with high doses has been observed. Pseudomembraneous colitis has been reported with clarithromycin use. Allergic reactions ranging from urticaria and mild skin eruptions to rare cases of anaphylaxis and Stevens-Johnson syndrome have also occurred. Rare cases of severe hepatic dysfunctions also have been reported. Hepatic failure is usually reversible, but fatalities have been reported. Clarithromycin may also cause tooth decolouration which may be removed by dental cleaning. Fetal abnormalities, such as cardiovascular defects, cleft palate and fetal growth retardation, have been observed in animals. Clarithromycin may cause QT prolongation.
Affected organisms
  • Enteric bacteria and other eubacteria
  • Mycobacterium
  • Streptococcus pyogenes
  • Streptococcus pneumoniae
  • Haemophilus influenzae
  • Helicobacter pylori
  • Mycobacterium leprae
  • Mycobacterium avium
Pathways
PathwayCategorySMPDB ID
Clarithromycin Action PathwayDrug actionSMP00248
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Clarithromycin.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Clarithromycin.Experimental, Illicit
3,4-DichloroisocoumarinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Clarithromycin.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Clarithromycin.Experimental, Illicit
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Clarithromycin.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Clarithromycin.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Clarithromycin.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Clarithromycin.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Clarithromycin.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Clarithromycin.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Clarithromycin.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Clarithromycin.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Clarithromycin.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Clarithromycin.Approved
AldosteroneThe serum concentration of Clarithromycin can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Clarithromycin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Clarithromycin.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Clarithromycin.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Clarithromycin.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Clarithromycin.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Clarithromycin.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Clarithromycin.Approved, Investigational
AlogliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Alogliptin.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Clarithromycin.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Clarithromycin.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Clarithromycin.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Clarithromycin.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Clarithromycin.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Clarithromycin.Experimental
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Clarithromycin.Approved
Aminohippuric acidThe serum concentration of Clarithromycin can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clarithromycin.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Clarithromycin.Approved
AmiodaroneClarithromycin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Clarithromycin.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Clarithromycin.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Clarithromycin.Approved
AmprenavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Amprenavir.Approved
AmrinoneThe metabolism of Amrinone can be decreased when combined with Clarithromycin.Approved
AmsacrineThe serum concentration of Clarithromycin can be increased when it is combined with Amsacrine.Approved
AnagrelideClarithromycin may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Clarithromycin.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clarithromycin.Approved
Antithrombin III humanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Antithrombin III human.Approved
AnvirzelThe serum concentration of Anvirzel can be increased when it is combined with Clarithromycin.Investigational
ApixabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Apixaban.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Clarithromycin.Approved, Investigational
AprepitantThe serum concentration of Clarithromycin can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArformoterolArformoterol may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
ArgatrobanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Clarithromycin.Approved, Investigational
ArmodafinilThe metabolism of Clarithromycin can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideClarithromycin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherClarithromycin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineClarithromycin may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Clarithromycin.Approved, Withdrawn
AsunaprevirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Asunaprevir.Approved, Investigational
AtazanavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Clarithromycin.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Clarithromycin.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Clarithromycin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Clarithromycin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Clarithromycin.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Clarithromycin.Approved
AzelnidipineThe metabolism of Azelnidipine can be decreased when combined with Clarithromycin.Approved
AzimilideThe metabolism of Azimilide can be decreased when combined with Clarithromycin.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Clarithromycin.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Clarithromycin.Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Clarithromycin.Approved
BatimastatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Batimastat.Experimental
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Clarithromycin.Investigational
BeclomethasoneThe serum concentration of Beclomethasone can be increased when it is combined with Clarithromycin.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Clarithromycin.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Clarithromycin.Approved
BenazeprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benazepril.Approved, Investigational
BenidipineThe metabolism of Benidipine can be decreased when combined with Clarithromycin.Approved
BenzamidineThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benzamidine.Experimental
BenzocaineThe serum concentration of Clarithromycin can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Clarithromycin.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clarithromycin.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Clarithromycin.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
BexaroteneThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Clarithromycin.Approved
Bi201335The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Bi201335.Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Clarithromycin.Approved
BiperidenThe serum concentration of Clarithromycin can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Clarithromycin.Approved
BivalirudinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Clarithromycin.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Clarithromycin.Approved, Investigational
BosentanThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Clarithromycin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clarithromycin.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Clarithromycin.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Clarithromycin.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Clarithromycin.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Clarithromycin.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clarithromycin.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Clarithromycin.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Clarithromycin.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Clarithromycin.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Clarithromycin.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Clarithromycin.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Clarithromycin.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Clarithromycin.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Clarithromycin.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Clarithromycin.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Clarithromycin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Clarithromycin.Approved
CaiThe metabolism of Cai can be decreased when combined with Clarithromycin.Investigational
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Clarithromycin.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Clarithromycin.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Clarithromycin.Approved
CandesartanThe serum concentration of Clarithromycin can be increased when it is combined with Candesartan.Approved
CandoxatrilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Candoxatril.Experimental
CandoxatrilatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Candoxatrilat.Experimental
CaptoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Captopril.Approved
CarbamazepineThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Clarithromycin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Clarithromycin.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Clarithromycin.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Clarithromycin.Approved, Investigational
CaspofunginThe serum concentration of Clarithromycin can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Clarithromycin.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Clarithromycin.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Clarithromycin.Approved, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Clarithromycin.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Clarithromycin.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Clarithromycin.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Clarithromycin.Approved
ChloramphenicolThe metabolism of Clarithromycin can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Clarithromycin.Approved, Illicit
ChloroquineChloroquine may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Clarithromycin.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
ChlorpropamideThe serum concentration of Clarithromycin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Clarithromycin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Clarithromycin.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Clarithromycin.Approved, Nutraceutical
CholesterolThe serum concentration of Clarithromycin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Clarithromycin can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Clarithromycin.Approved, Investigational
CilastatinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Cilastatin.Approved
CilazaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be decreased when combined with Clarithromycin.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Clarithromycin.Approved
CimetidineThe serum concentration of Clarithromycin can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Clarithromycin.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Clarithromycin.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Clarithromycin.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Clarithromycin.Approved
CitalopramClarithromycin may increase the QTc-prolonging activities of Citalopram.Approved
ClemastineThe metabolism of Clarithromycin can be decreased when combined with Clemastine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Clarithromycin.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Clarithromycin.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Clarithromycin.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Clarithromycin.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Clarithromycin.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Clarithromycin.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Clarithromycin.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Clarithromycin.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Clarithromycin.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Clarithromycin.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Clarithromycin.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Clarithromycin.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Clarithromycin.Approved, Illicit
ClotrimazoleThe metabolism of Clarithromycin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Clarithromycin.Approved
CobicistatThe serum concentration of Cobicistat can be increased when it is combined with Clarithromycin.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Clarithromycin.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Clarithromycin.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Clarithromycin.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Clarithromycin.Approved
ColforsinThe serum concentration of Clarithromycin can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Clarithromycin.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Clarithromycin.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Clarithromycin.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Clarithromycin.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Clarithromycin.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Clarithromycin.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Clarithromycin.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Clarithromycin.Approved
DabrafenibThe serum concentration of Clarithromycin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Clarithromycin.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Clarithromycin.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Clarithromycin.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Clarithromycin.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Clarithromycin.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Clarithromycin.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Clarithromycin.Approved, Investigational
DarodipineThe metabolism of Darodipine can be decreased when combined with Clarithromycin.Experimental
DarunavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Clarithromycin.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Clarithromycin.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Clarithromycin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Clarithromycin.Approved
DeferasiroxThe serum concentration of Clarithromycin can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Clarithromycin.Approved
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Clarithromycin.Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Clarithromycin.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Clarithromycin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Clarithromycin.Approved
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Clarithromycin.Approved
DesloratadineThe serum concentration of Clarithromycin can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Clarithromycin.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Clarithromycin.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Clarithromycin.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Clarithromycin.Approved
DexamethasoneThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Clarithromycin.Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Clarithromycin.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Clarithromycin.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Clarithromycin.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Clarithromycin.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Clarithromycin.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Clarithromycin.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Clarithromycin.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Clarithromycin.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Clarithromycin.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Clarithromycin.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Clarithromycin.Approved
DigoxinThe metabolism of Digoxin can be decreased when combined with Clarithromycin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Clarithromycin.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Clarithromycin.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Clarithromycin.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Clarithromycin.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Clarithromycin.Approved
DipyridamoleThe serum concentration of Clarithromycin can be increased when it is combined with Dipyridamole.Approved
DisopyramideClarithromycin may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Clarithromycin.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Clarithromycin.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Clarithromycin.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Clarithromycin.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Clarithromycin.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Clarithromycin.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Clarithromycin.Approved
DotarizineThe metabolism of Dotarizine can be decreased when combined with Clarithromycin.Investigational
DoxazosinThe serum concentration of Clarithromycin can be increased when it is combined with Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Clarithromycin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Clarithromycin.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Clarithromycin.Approved, Investigational
DoxycyclineThe metabolism of Clarithromycin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Clarithromycin.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Clarithromycin.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Clarithromycin.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Clarithromycin.Approved, Investigational
EcabetThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Clarithromycin.Approved
EfavirenzThe serum concentration of Clarithromycin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be decreased when combined with Clarithromycin.Approved
ElafinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Elafin.Investigational
ElbasvirThe serum concentration of Clarithromycin can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Clarithromycin.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Clarithromycin.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Clarithromycin.Approved
EnalaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalapril.Approved, Vet Approved
EnalaprilatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalaprilat.Approved
EnalkirenThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalkiren.Experimental
EnzalutamideThe serum concentration of Clarithromycin can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe metabolism of Eperisone can be decreased when combined with Clarithromycin.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Clarithromycin.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Clarithromycin.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Clarithromycin.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Clarithromycin.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Clarithromycin.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Clarithromycin.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Clarithromycin.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Clarithromycin.Approved
EribulinEribulin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Clarithromycin.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
EscitalopramClarithromycin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Clarithromycin.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Clarithromycin.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Clarithromycin.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Clarithromycin.Approved
EstriolThe serum concentration of Clarithromycin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Clarithromycin.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Clarithromycin.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Clarithromycin.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Clarithromycin.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Clarithromycin.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Clarithromycin.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Clarithromycin.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clarithromycin.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Clarithromycin.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Clarithromycin.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Clarithromycin.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Clarithromycin.Approved, Investigational
EtravirineThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Clarithromycin.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Clarithromycin.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Clarithromycin.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Clarithromycin.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Clarithromycin.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Clarithromycin.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Clarithromycin.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Clarithromycin.Approved, Investigational
FendilineThe metabolism of Fendiline can be decreased when combined with Clarithromycin.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Clarithromycin.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Clarithromycin.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clarithromycin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Clarithromycin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Clarithromycin.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Clarithromycin.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Clarithromycin.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Clarithromycin.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Clarithromycin.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Clarithromycin.Investigational
FluconazoleThe metabolism of Clarithromycin can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Clarithromycin.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Clarithromycin.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Clarithromycin.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Clarithromycin.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Clarithromycin.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Clarithromycin.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Clarithromycin.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Clarithromycin.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Clarithromycin.Approved
FluoxetineClarithromycin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolClarithromycin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Clarithromycin can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Clarithromycin.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Clarithromycin.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Clarithromycin.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Clarithromycin.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Clarithromycin.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Clarithromycin.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Clarithromycin.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Clarithromycin.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Clarithromycin.Approved
FluvoxamineThe metabolism of Clarithromycin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Clarithromycin.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clarithromycin can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Clarithromycin.Approved
FosinoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Fosinopril.Approved
FosphenytoinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Clarithromycin.Approved, Investigational
Fusidic AcidThe serum concentration of Clarithromycin can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe metabolism of Gabapentin can be decreased when combined with Clarithromycin.Approved, Investigational
GabexateThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Gabexate.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Clarithromycin.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Clarithromycin.Approved
GallopamilThe metabolism of Gallopamil can be decreased when combined with Clarithromycin.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Clarithromycin.Approved, Investigational
GeldanamycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Clarithromycin.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Clarithromycin.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
GenisteinThe serum concentration of Clarithromycin can be increased when it is combined with Genistein.Investigational
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Clarithromycin.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Clarithromycin.Approved
GlycerolThe serum concentration of Clarithromycin can be increased when it is combined with Glycerol.Experimental
GM6001The therapeutic efficacy of Clarithromycin can be decreased when used in combination with GM6001.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Clarithromycin.Approved
Gramicidin DThe serum concentration of Clarithromycin can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Clarithromycin.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Clarithromycin.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Clarithromycin.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Clarithromycin.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Clarithromycin.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Clarithromycin.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Clarithromycin.Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Clarithromycin.Approved
HirulogThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Hirulog.Experimental
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Clarithromycin.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Clarithromycin.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Clarithromycin.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Clarithromycin.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Clarithromycin.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Clarithromycin.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Clarithromycin.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Clarithromycin.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Clarithromycin.Approved
IbutilideClarithromycin may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Clarithromycin can be increased when it is combined with Idelalisib.Approved
idraparinuxThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Clarithromycin resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Clarithromycin.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Clarithromycin.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Clarithromycin.Approved
ImidaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Clarithromycin.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Clarithromycin.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Clarithromycin.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Clarithromycin.Approved
IndinavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Clarithromycin.Approved, Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Clarithromycin.Approved
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Clarithromycin.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Clarithromycin.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Clarithromycin can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clarithromycin.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clarithromycin.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Clarithromycin.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Clarithromycin.Investigational
ItraconazoleThe metabolism of Clarithromycin can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Clarithromycin.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Clarithromycin.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Clarithromycin.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Clarithromycin.Approved, Investigational
IxazomibThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ixazomib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Clarithromycin.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Clarithromycin.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Clarithromycin.Approved
KetoconazoleThe metabolism of Clarithromycin can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineThe metabolism of Lacidipine can be decreased when combined with Clarithromycin.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Clarithromycin.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Clarithromycin.Approved, Investigational
LamotrigineThe metabolism of Lamotrigine can be decreased when combined with Clarithromycin.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Clarithromycin.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Clarithromycin.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Clarithromycin.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Clarithromycin.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Clarithromycin.Approved
LenvatinibClarithromycin may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lepirudin.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Clarithromycin.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Clarithromycin.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Clarithromycin.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Clarithromycin.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Clarithromycin.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Clarithromycin.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Clarithromycin.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Clarithromycin.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Clarithromycin.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Clarithromycin.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin.Approved
LiothyronineThe serum concentration of Clarithromycin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Clarithromycin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Clarithromycin.Approved
LithiumLithium may increase the QTc-prolonging activities of Clarithromycin.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Clarithromycin.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Clarithromycin.Approved
LopinavirClarithromycin may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Clarithromycin.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Clarithromycin.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Clarithromycin.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Clarithromycin.Approved, Investigational
LuliconazoleThe serum concentration of Clarithromycin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Clarithromycin.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Clarithromycin.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Clarithromycin.Approved
Magnesium SulfateThe metabolism of Magnesium Sulfate can be decreased when combined with Clarithromycin.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be decreased when combined with Clarithromycin.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Clarithromycin.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Clarithromycin.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Clarithromycin.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Clarithromycin.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Clarithromycin.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Clarithromycin.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Clarithromycin.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Clarithromycin.Approved
Megestrol acetateThe serum concentration of Clarithromycin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Clarithromycin.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Clarithromycin.Approved, Vet Approved
MeprobamateThe serum concentration of Clarithromycin can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneMethadone may increase the QTc-prolonging activities of Clarithromycin.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Clarithromycin.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Clarithromycin.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Clarithromycin.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Clarithromycin.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clarithromycin.Approved, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Clarithromycin.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Clarithromycin.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Clarithromycin.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Clarithromycin.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Clarithromycin.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Clarithromycin.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Clarithromycin.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Clarithromycin.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Clarithromycin.Approved
MitomycinThe serum concentration of Clarithromycin can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Clarithromycin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Clarithromycin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Clarithromycin can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Modafinil.Approved, Investigational
MoexiprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Moexipril.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Clarithromycin.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Clarithromycin.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Clarithromycin.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololThe serum concentration of Nadolol can be increased when it is combined with Clarithromycin.Approved
NafamostatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nafamostat.Investigational
NafcillinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Nafcillin.Approved
NaftopidilThe metabolism of Naftopidil can be decreased when combined with Clarithromycin.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Clarithromycin.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Clarithromycin.Approved, Vet Approved
NaltrexoneThe serum concentration of Clarithromycin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Clarithromycin can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Clarithromycin.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Clarithromycin.Investigational
NCX 4016The therapeutic efficacy of Clarithromycin can be decreased when used in combination with NCX 4016.Investigational
NefazodoneThe metabolism of Clarithromycin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nelfinavir.Approved
NeostigmineThe serum concentration of Clarithromycin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Clarithromycin can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Clarithromycin.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Clarithromycin.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Clarithromycin.Approved
NiguldipineThe metabolism of Niguldipine can be decreased when combined with Clarithromycin.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Clarithromycin.Approved, Investigational
NiludipineThe metabolism of Niludipine can be decreased when combined with Clarithromycin.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Clarithromycin.Approved
NimesulideThe metabolism of Nimesulide can be decreased when combined with Clarithromycin.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Clarithromycin.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Clarithromycin.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Clarithromycin.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Clarithromycin.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Clarithromycin.Approved
NitroaspirinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nitroaspirin.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Clarithromycin.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Clarithromycin.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Clarithromycin.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Clarithromycin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Clarithromycin.Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Clarithromycin.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Clarithromycin.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Clarithromycin.Approved
OmapatrilatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Clarithromycin.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Clarithromycin.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Clarithromycin.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Clarithromycin.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Clarithromycin.Approved
OtamixabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Clarithromycin.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Clarithromycin.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Clarithromycin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
P-NitrophenolThe serum concentration of Clarithromycin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Clarithromycin.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Clarithromycin.Approved
PaliperidoneClarithromycin may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Clarithromycin can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Clarithromycin.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Clarithromycin.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Clarithromycin.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Clarithromycin.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Clarithromycin.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Clarithromycin.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Clarithromycin.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Clarithromycin.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Clarithromycin.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Clarithromycin.Approved
PentobarbitalThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Clarithromycin.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Clarithromycin.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Clarithromycin.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Clarithromycin.Approved
PerindoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Clarithromycin.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Clarithromycin.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Clarithromycin.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Clarithromycin.Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Clarithromycin.Approved
PhenobarbitalThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Clarithromycin.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Clarithromycin.Approved
PhenytoinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Phenytoin.Approved, Vet Approved
PhosphoramidonThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Phosphoramidon.Experimental
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clarithromycin.Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Clarithromycin.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Clarithromycin.Approved, Investigational
PimozideClarithromycin may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Clarithromycin.Withdrawn
PinaveriumThe metabolism of Pinaverium can be decreased when combined with Clarithromycin.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Clarithromycin.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Clarithromycin.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Clarithromycin.Approved
Platelet Activating FactorThe serum concentration of Clarithromycin can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Clarithromycin.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Clarithromycin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Clarithromycin.Approved
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Clarithromycin.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Clarithromycin.Approved, Nutraceutical
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Clarithromycin resulting in a loss in efficacy.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Clarithromycin.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Clarithromycin.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Clarithromycin.Approved, Vet Approved
PrazosinThe serum concentration of Clarithromycin can be increased when it is combined with Prazosin.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Clarithromycin.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Clarithromycin.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
PregabalinThe metabolism of Pregabalin can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Clarithromycin.Experimental
PrenylamineThe metabolism of Prenylamine can be decreased when combined with Clarithromycin.Withdrawn
PrimaquinePrimaquine may increase the QTc-prolonging activities of Clarithromycin.Approved
PrimidoneThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Primidone.Approved, Vet Approved
PrinomastatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Prinomastat.Investigational
ProbenecidThe serum concentration of Clarithromycin can be increased when it is combined with Probenecid.Approved
ProcainamideClarithromycin may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Clarithromycin.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Clarithromycin.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Clarithromycin.Approved
PromazinePromazine may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Clarithromycin.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Clarithromycin.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Clarithromycin.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Clarithromycin.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Clarithromycin.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Clarithromycin.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Clarithromycin.Approved, Illicit
QuercetinThe serum concentration of Clarithromycin can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Clarithromycin.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Clarithromycin.Approved
QuinaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Quinapril.Approved, Investigational
QuinidineClarithromycin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Clarithromycin.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Clarithromycin.Approved, Investigational
RacecadotrilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Racecadotril.Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Clarithromycin.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Clarithromycin.Approved, Investigational
RamiprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ramipril.Approved
RanitidineThe serum concentration of Clarithromycin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Clarithromycin.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Clarithromycin.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Clarithromycin.Approved
RemikirenThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Remikiren.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Clarithromycin.Approved, Investigational
ReserpineThe serum concentration of Clarithromycin can be decreased when it is combined with Reserpine.Approved
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Clarithromycin.Approved
RifabutinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Rifabutin.Approved
RifampicinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Rifampicin.Approved
RifapentineThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Clarithromycin.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Clarithromycin.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Clarithromycin.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Clarithromycin.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Clarithromycin.Approved
RisedronateThe metabolism of Risedronate can be decreased when combined with Clarithromycin.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Clarithromycin.Approved, Investigational
RitonavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Clarithromycin.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Clarithromycin.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Clarithromycin.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Clarithromycin.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Clarithromycin.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clarithromycin.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Clarithromycin.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Clarithromycin.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Clarithromycin.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Clarithromycin.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Clarithromycin.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Clarithromycin.Approved
SaquinavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Saxagliptin.Approved
ScopolamineThe serum concentration of Clarithromycin can be increased when it is combined with Scopolamine.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Clarithromycin.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Clarithromycin.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Clarithromycin.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Clarithromycin.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Clarithromycin.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Clarithromycin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Clarithromycin.Approved
SiltuximabThe serum concentration of Clarithromycin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Clarithromycin.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Clarithromycin.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Clarithromycin.Approved, Investigational
SitagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Sitagliptin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Clarithromycin.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Clarithromycin.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Clarithromycin.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Clarithromycin.Approved, Investigational
SotalolClarithromycin may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Clarithromycin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Clarithromycin.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Clarithromycin.Approved
SpiraprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Spirapril.Approved
SpironolactoneThe serum concentration of Clarithromycin can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Clarithromycin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Clarithromycin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Clarithromycin can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Clarithromycin can be decreased when it is combined with Streptozocin.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Clarithromycin.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Clarithromycin.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Clarithromycin.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Clarithromycin.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
SumatriptanThe serum concentration of Clarithromycin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Clarithromycin.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Clarithromycin.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Clarithromycin.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Clarithromycin.Approved
TacrineThe serum concentration of Clarithromycin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Clarithromycin.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Clarithromycin.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Clarithromycin.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Clarithromycin.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Clarithromycin.Approved, Investigational
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Clarithromycin.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Clarithromycin.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Clarithromycin.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Clarithromycin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Clarithromycin.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Clarithromycin.Approved
TelavancinClarithromycin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Clarithromycin.Approved
TelmisartanThe serum concentration of Clarithromycin can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Clarithromycin.Approved
TemocaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Temsirolimus.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Clarithromycin.Approved
TerazosinThe serum concentration of Clarithromycin can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Clarithromycin.Approved
TerfenadineClarithromycin may increase the QTc-prolonging activities of Terfenadine.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Clarithromycin.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Clarithromycin.Approved, Investigational
TetrabenazineClarithromycin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Clarithromycin.Approved, Vet Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Clarithromycin.Approved
ThioridazineClarithromycin may increase the QTc-prolonging activities of Thioridazine.Approved
ThiorphanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Clarithromycin.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Clarithromycin.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Clarithromycin.Approved
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Clarithromycin resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Clarithromycin.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Clarithromycin.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Clarithromycin.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Clarithromycin.Approved
TipranavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Clarithromycin.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Clarithromycin.Approved
TocilizumabThe serum concentration of Clarithromycin can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Clarithromycin.Approved, Investigational
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be decreased when combined with Clarithromycin.Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Clarithromycin.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Clarithromycin.Approved
TopiramateThe metabolism of Clarithromycin can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Clarithromycin.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Clarithromycin.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Clarithromycin.Approved, Investigational
TrandolaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Trandolapril.Approved
TranilastThe metabolism of Tranilast can be decreased when combined with Clarithromycin.Approved, Investigational
TranylcypromineThe metabolism of Clarithromycin can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Clarithromycin.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Clarithromycin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Clarithromycin.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Clarithromycin.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Clarithromycin.Approved
TrifluoperazineThe serum concentration of Clarithromycin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Clarithromycin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Clarithromycin.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Clarithromycin.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Clarithromycin.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Clarithromycin.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Clarithromycin.Approved
UbenimexThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ubenimex.Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Clarithromycin.Approved, Investigational
UlinastatinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Clarithromycin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Clarithromycin.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Clarithromycin.Investigational, Withdrawn
VandetanibClarithromycin may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Clarithromycin.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Clarithromycin.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Clarithromycin.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Clarithromycin.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Clarithromycin.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Clarithromycin.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Clarithromycin.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Clarithromycin.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Clarithromycin.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Clarithromycin.Approved
VildagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Clarithromycin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Clarithromycin.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Clarithromycin.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Clarithromycin.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Clarithromycin.Approved, Investigational
VinpocetineThe metabolism of Vinpocetine can be decreased when combined with Clarithromycin.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Clarithromycin.Approved
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Clarithromycin.Approved
VoriconazoleThe metabolism of Clarithromycin can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Clarithromycin.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Clarithromycin.Approved
XimelagatranThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe metabolism of Xylometazoline can be decreased when combined with Clarithromycin.Approved
Ym150The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ym150.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Clarithromycin.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Clarithromycin.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Clarithromycin.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational
ZiconotideThe metabolism of Ziconotide can be decreased when combined with Clarithromycin.Approved
ZidovudineClarithromycin may increase the myelosuppressive activities of Zidovudine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Clarithromycin.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Clarithromycin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneClarithromycin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Clarithromycin.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Clarithromycin.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Clarithromycin.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Clarithromycin.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Clarithromycin.Approved, Investigational
Food Interactions
  • Biaxin - take without regard to meals (however absorption appears to be improved when drug is taken with food).
  • Biaxin XL - take with a meal, taking it on an empty stomach is associated with total product exposure 30% inferior to that observed when administered with food.
References
Synthesis Reference

Jih-Hua Liu, David A. Riley, “Preparation of crystal form II of clarithromycin.” U.S. Patent US5844105, issued May, 1997.

US5844105
General References
  1. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H: Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007 Feb 10;369(9560):482-90. [PubMed:17292768 ]
  2. Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x. doi: 10.1016/j.idc.2009.06.013. [PubMed:19909895 ]
  3. Piscitelli SC, Danziger LH, Rodvold KA: Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm. 1992 Feb;11(2):137-52. [PubMed:1312921 ]
  4. Peters DH, Clissold SP: Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992 Jul;44(1):117-64. [PubMed:1379907 ]
  5. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039 ]
  6. Stephenson GA, Stowell JG, Toma PH, Pfeiffer RR, Byrn SR: Solid-state investigations of erythromycin A dihydrate: structure, NMR spectroscopy, and hygroscopicity. J Pharm Sci. 1997 Nov;86(11):1239-44. [PubMed:9383733 ]
External Links
ATC CodesA02BD05A02BD06J01FA09A02BD11A02BD04A02BD07A02BD09
AHFS Codes
  • 08:12.12.92
PDB EntriesNot Available
FDA labelDownload (376 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5434
Blood Brain Barrier-0.987
Caco-2 permeable-0.8674
P-glycoprotein substrateSubstrate0.7714
P-glycoprotein inhibitor IInhibitor0.8475
P-glycoprotein inhibitor IINon-inhibitor0.622
Renal organic cation transporterNon-inhibitor0.8987
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9161
CYP450 3A4 substrateSubstrate0.6672
CYP450 1A2 substrateNon-inhibitor0.8973
CYP450 2C9 inhibitorNon-inhibitor0.8851
CYP450 2D6 inhibitorNon-inhibitor0.9258
CYP450 2C19 inhibitorNon-inhibitor0.8835
CYP450 3A4 inhibitorNon-inhibitor0.5524
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.898
Ames testNon AMES toxic0.8967
CarcinogenicityNon-carcinogens0.9294
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7236 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9883
hERG inhibition (predictor II)Non-inhibitor0.9038
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Granule, for suspensionOral125 mg
Granule, for suspensionOral250 mg
Granule, for suspensionOral250 mg/5mL
Tablet, film coated, extended releaseOral500 mg/1
Tablet, extended releaseOral500 mg
For suspensionOral125 mg/5mL
For suspensionOral250 mg/5mL
Granule, for suspensionOral125 mg/5mL
TabletOral250 mg/1
TabletOral500 mg/1
Tablet, coatedOral250 mg/1
Tablet, coatedOral500 mg/1
Tablet, extended releaseOral500 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
Capsule; capsule, extended release; kit; tabletOral
Kit
TabletOral250 mg
TabletOral500 mg
Prices
Unit descriptionCostUnit
Biaxin 60 250 mg tablet Bottle379.5USD bottle
Clarithromycin 250 mg/5ml Suspension 100ml Bottle86.23USD bottle
Clarithromycin 250 mg/5ml Suspension 50ml Bottle46.56USD bottle
Clarithromycin 125 mg/5ml Suspension 100ml Bottle45.24USD bottle
Clarithromycin 125 mg/5ml Suspension 50ml Bottle27.99USD bottle
Biaxin XL 500 mg 24 Hour tablet6.77USD tablet
Biaxin xl 500 mg tablet6.57USD tablet
Biaxin 250 mg tablet6.42USD tablet
Biaxin 500 mg tablet6.37USD tablet
Clarithromycin 500 mg 24 Hour tablet5.21USD tablet
Clarithromycin er 500 mg tablet5.01USD tablet
Clarithromycin 250 mg tablet4.61USD tablet
Clarithromycin 500 mg tablet4.61USD tablet
Biaxin Bid 500 mg Tablet3.41USD tablet
Biaxin Xl 500 mg Extended-Release Tablet2.63USD tablet
Mylan-Clarithromycin 500 mg Tablet1.91USD tablet
Pms-Clarithromycin 500 mg Tablet1.91USD tablet
Ratio-Clarithromycin 500 mg Tablet1.91USD tablet
Sandoz Clarithromycin 500 mg Tablet1.91USD tablet
Biaxin Bid 250 mg Tablet1.73USD tablet
Clarithromycin 100% powder1.56USD g
Biaxin 50 mg/ml Suspension0.59USD ml
Biaxin 25 mg/ml Suspension0.3USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1328609 No1994-04-192011-04-19Canada
CA2471102 No2005-02-082017-07-25Canada
US6010718 No1997-04-112017-04-11Us
US6551616 No1997-06-152017-06-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point220 dec °CPhysProp
water solubility0.33 mg/LNot Available
logP3.16MCFARLAND,JW ET AL. (1997)
pKa8.99 (at 25 °C)MCFARLAND,JW ET AL. (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.217 mg/mLALOGPS
logP3.18ALOGPS
logP3.24ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.46ChemAxon
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area182.91 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity190.79 m3·mol-1ChemAxon
Polarizability82.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolides and analogues
Sub ClassNot Available
Direct ParentMacrolides and analogues
Alternative Parents
Substituents
  • Macrolide
  • Amino sugar
  • Desosamine
  • Amino saccharide
  • Oxane
  • Monosaccharide
  • Tertiary alcohol
  • Cyclic ketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Lactone
  • Ketone
  • Carboxylic acid ester
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Shigella flexneri
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of ribosome
Specific Function:
Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA (By similarity).Forms part of the ribosomal stalk, playing a central role in the interaction of the ribosome with GTP-bound translation factors.
Gene Name:
rplJ
Uniprot ID:
P0A7J6
Molecular Weight:
17711.38 Da
References
  1. Morimura T, Hashiba M, Kameda H, Takami M, Takahama H, Ohshige M, Sugawara F: Identification of macrolide antibiotic-binding Human_p8 protein. J Antibiot (Tokyo). 2008 May;61(5):291-6. doi: 10.1038/ja.2008.41. [PubMed:18653994 ]
  2. Champney WS, Burdine R: Macrolide antibiotic inhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells. Microb Drug Resist. 1998 Fall;4(3):169-74. [PubMed:9818968 ]
  3. Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x. doi: 10.1016/j.idc.2009.06.013. [PubMed:19909895 ]
  4. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039 ]
  5. Champney WS, Burdine R: Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother. 1995 Sep;39(9):2141-4. [PubMed:8540733 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Keseru GM: Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5. [PubMed:12873512 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP: Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol. 2013 Jun;83(6):1257-67. doi: 10.1124/mol.112.084152. Epub 2013 Apr 9. [PubMed:23571415 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP: Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol. 2013 Jun;83(6):1257-67. doi: 10.1124/mol.112.084152. Epub 2013 Apr 9. [PubMed:23571415 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x. doi: 10.1016/j.idc.2009.06.013. [PubMed:19909895 ]
  2. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305 ]
  5. Fontana E, Dansette PM, Poli SM: Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab. 2005 Oct;6(5):413-54. [PubMed:16248836 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  3. Egashira K, Ohtani H, Itoh S, Koyabu N, Tsujimoto M, Murakami H, Sawada Y: Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos. 2004 Aug;32(8):828-33. [PubMed:15258108 ]
  4. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039 ]
  5. Dey S, Gunda S, Mitra AK: Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J Pharmacol Exp Ther. 2004 Oct;311(1):246-55. Epub 2004 Jun 2. [PubMed:15175422 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T: Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22. Epub 2005 Feb 11. [PubMed:15708966 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:39